Drugs / Cis-Retinoic acid
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05384821 | Sep 2022 → May 2028 expected | Wilms tumor | Centre Oscar Lambret | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00200161 Background | Aug 2005 → May 2017 | glioblastoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cis-Retinoic acid | “Maintenance cis-retinoic acid.” NCT00200161 ↗ |
| Route | Oral | “Oral, 2 weeks in a row, thrice per cycle (D15 to D28, D43 to D56, D71 to D84)” NCT05384821 ↗ |